Actively Recruiting
New AI-based Technologies in Nuclear Medicine
Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2025-09-15
1500
Participants Needed
1
Research Sites
243 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.
CONDITIONS
Official Title
New AI-based Technologies in Nuclear Medicine
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing PET/CT scans or therapeutic treatments with radiopharmaceuticals labeled with alpha or beta emitting nuclides
You will not qualify if you...
- Patients whose clinical or psychological conditions do not allow for their involvement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy
Actively Recruiting
Research Team
M
Mauro Iori, MD
CONTACT
F
Federica Fioroni, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here